Radiopharm Theranostics Limited (ASX:RAD) has disclosed changes to the relevant interests of three directors — Bruce Goodwin, Ian Turner, and Paul Hopper — following the cancellation of listed options on 16 October 2026, with each director disposing of 1,111,111 listed options expiring 31 July 2029 at an exercise price of $0.018 for nil consideration.
Key Points
- Three directors — Bruce Goodwin, Ian Turner, and Paul Hopper — each had 1,111,111 listed options cancelled on 16 October 2026.
- The cancelled options were listed options expiring 31 July 2029 with an exercise price of $0.018, disposed of for nil consideration.
- Bruce Goodwin's indirect options holding via Sundial Management Pty Limited reduced from 2,777,778 to 1,666,667, with his indirect share holding remaining at 2,777,778.
- Ian Turner's total options holding reduced from 24,805,126 to 23,694,015, with his total share holding remaining at 12,763,070.
- The nature of change in all cases was recorded as cancellation of listed options, and none of the trades occurred during a closed period.
Bruce Goodwin's Interest Change via Sundial Management
Director Bruce Goodwin's change of interest was recorded as indirect, held through Sundial Management Pty Limited, of which Mr Goodwin is a director and shareholder. Prior to the change on 16 October 2026, Goodwin held 2,777,778 shares and 2,777,778 options indirectly. Following the cancellation of 1,111,111 listed options expiring 31 July 2029 at an exercise price of $0.018, his indirect options holding reduced to 1,666,667. His indirect share holding of 2,777,778 remained unchanged. No consideration was received for the disposal.
Ian Turner's Direct and Indirect Securities After Cancellation
Director Ian Turner held both direct and indirect interests prior to the 16 October 2026 change. His total securities prior to the change comprised 12,763,070 shares and 24,805,126 options across direct and indirect holdings. Following the cancellation of 1,111,111 listed options expiring 31 July 2029 at an exercise price of $0.018, his direct options reduced from 23,179,148 to 22,068,037, while indirect options remained at 1,625,978. His total options holding after the change was 23,694,015. The indirect interest is held through a superannuation fund. No consideration was received.
Filing Details and Closed Period Confirmation
All three Change of Director's Interest Notices were lodged by Radiopharm Theranostics Limited (ABN 57 647 877 889) under ASX Listing Rule 3.19A.2 and section 205G of the Corporations Act. For each director, the date of the last previous notice was recorded as 22 September 2026. The filings confirm that none of the interests in securities were traded during a closed period where prior written clearance was required. No changes to director interests in contracts were recorded, with all contract-related fields marked as not applicable.



Please wait processing your request...